[177Lu]Lu-PSMA-617
Sponsors
Novartis Pharmaceuticals, University Hospital, Essen
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Neuroendocrine Prostate CancerVery High Risk Prostate Carcinoma
Phase 1
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Active, not recruitingNCT06379217
Start: 2024-07-29End: 2026-08-27Updated: 2026-03-11
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
TerminatedNCT06388369
Start: 2025-08-25End: 2026-03-09Updated: 2026-03-13
Phase 2
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Active, not recruitingNCT05658003
Start: 2023-05-05End: 2027-01-13Updated: 2026-03-23
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
Active, not recruitingNCT05670106
Start: 2023-05-16End: 2026-06-30Updated: 2026-02-13